MikeWardImage

Hi, I’m Mike Ward, founder of the National Institute for Cannabis Investors.

The Institute here in Baltimore is now the #1 resource for anyone interested in what could soon be a $1 trillion industry.

Our advisory board members include the sector’s top CEOs, doctors, angel investors and venture capitalists.

In fact, Michael Robinson, one of the top cannabis venture capital experts in the country, is here with me today.

Together, we’re going to show you something you’ve never seen before.

You see, as the #1 source for cannabis investing, we constantly hear from small, privately held cannabis companies…

  • It might be a small grower who thinks they’re the next Canopy or Aurora…
  • It might be a cannabis tech firm that’s invented a new vape pen…
  • Or it may be a company focused on the medicinal side of cannabis.

They reach out to us for advice on how to grow their business. We review their pitch decks, their marketing plans, and their leadership.

And, to be blunt, most of these firms have no chance.

However, a few times a year, something extraordinary happens...

We come across a startup that’s set to rock the entire cannabis industry.

We find what could be the next $1 billion company.

And, in this extreme case, what could be the next $52 billion company.

Which is why we’re here today.

We’re going to take you on a journey – right now – with a company that has the potential to go from a tiny grubstake … to a value of $52.5 billion dollars.

Now, this is nothing like buying a public stock. This is not about IPO investing.

Today, you’re going to discover the ins and outs of angel investing and venture capital.

This is an arena that only 0.1% of Americans ever step into.

Which is why it’s where many of America’s largest fortunes are created.

When you invest in private companies, you could make millions of dollars, even if they never go public.

If you want to know how you can get access to these kinds of deals…

Then keep watching, because you’re about to find out.

Because, in addition to Michael Robinson, you’ll be hearing from another titan of the cannabis industry.

A successful serial entrepreneur and a highly respected scientist who has taken multiple companies public, making their investors millions.

He’s going to show you why his new discovery could be one of the biggest medical breakthroughs of our lifetime…

A potential cure for one of today’s deadliest diseases.

He has video evidence to prove it.

This is the kind of startup that could turn a small investment into $1 million or more in the blink of an eye.

C_02

So buckle up… you’re about to see a side of the industry 99.9% of investors have never seen before... and will never see in the future.

This is moment in time cannabis disrupts the $1.1 trillion pharmaceutical industry…

And the man you’re about to meet has the patents to prove that, too.

He’s about to take advantage of an aspect of human biology that was only recently discovered, but affects every area of human health.

In fact, this new discovery could very well be the missing link to nearly every incurable disease.

You’ll see the video evidence for yourself in just a few moments.

First, with me now is my co-host, friend, and Institute Board Member, Michael Robinson.

Michael, thanks for joining me on this endeavor.

MichaelRobinsonImage

MICHAEL ROBINSON:

Happy to be here, Mike.

MIKE WARD:

Michael, you’ve worked with a number of startups over your 35-year career.

Everything from cloud computing to cyber security to the internet of things.

And you’ve been closely following the cannabis industry for a long time.

MICHAEL ROBINSON:

That’s right.

I first started watching this industry 20 years ago when my home state – California – passed medical marijuana legislation in 1996.

MIKE WARD:

That’s just one of the reasons you’re on the board here at the National Institute of Cannabis Investors.

And you’ve been instrumental in helping us identify cannabis stocks and IPOs.

It seems like every day we get another letter from folks telling us your cannabis recommendations made them $40,000…

I've made $42,000. Michael Robinson is hands down the best.
TOM CARLTON, TENNESSEE

Or $90,000…

I made over $90,000 from
Michael Robinson's pot stocks.
BILL LAMPROPOLOUS, ALBERTA

Or $150,000…

My marijuana stock portfolio is
up $150,000 thanks to Michael.
WILL PALMER, TEXAS

Our readers can’t stop raving about how much money you’ve helped them make.

My pot portfolio is up to
$100,000. Keep it up!
DAN LOCKLEER, VIRGINIA

MICHAEL ROBINSON:

Yeah, we’ve done pretty well on the public markets.

Just today, my subscribers pocketed another double-digit gain in a cannabis stock.

But investing in cannabis startups… this is a whole different game.

When you invest in a private company, you’re part of a much smaller group. You’re not just another shareholder. It’s not just another ticker symbol in a portfolio.

You’re buying a piece of a company directly.

So when one of your startups succeeds – whether they have a big IPO, or they get acquired – it’s much more rewarding.

It’s a personal victory.

And like I said, the rewards can be exponentially bigger.

MIKE WARD:

Can we get specific about that Michael… the rewards part?

MICHAEL ROBINSON:

To give you some idea, Mike, just take a look at T-G-O-D – commonly known as. TGOD.

Everybody’s heard me talk about the profits investors could have seen since their IPO.

C_03

But what people haven’t heard is the profits their private investors could have seen.

When TGOD was still in its startup phase, December of 2016, they sold private shares to a handful of ordinary folks. That was for just 50 cents each.

C_04

At IPO, those shares were already up 250%.

Today, those shares in the public market have run up as high as 1,948%.

MIKE WARD:

Michael that’s exceptional. You rarely see a return that big… I mean, most folks will never see the kinds of gains we’re showing today.

C_05

But a $10,000 investment when TGOD was still a private company would have turned into over $200,000 at the peak.

MICHAEL ROBINSON:

Or, Mike, take Tilray as an example.

Everybody’s heard about the huge gains you could have seen since they went public.

But almost no one knows they offered a few select investors shares for just $7.10 each when they were still a private startup.

C_06

If you had access to that offering – which not many people did – and you put in $10,000, you could have cashed out to a peak gain of over $412,000.

Or look at Canopy.

Everyone’s heard me talk about Canopy. They’re the largest cannabis producer in Canada.

But back in 2013, they sold private shares for just 59 cents a share.

Fast forward a little bit – they became the first “cannabis unicorn.” That means they reached a valuation of $1 billion dollars.

Their shares have been as high as $76.68.

C_07

So if you had access to that first private deal – you could have turned $10,000 into as much as $1.3 million.

C_08

MIKE WARD:

That’s what really stands out about investing in startups. The profits can be so much bigger.

We follow Canopy pretty closely here.

If you had bought shares at the IPO, your current peak gains would be 2,175%.

That’s incredible. It’s enough to grow $10,000 to $227,500.

But what if you were in six months earlier, when they were still a startup?

C_09

Your stake could be worth over $1 million more.

MICHAEL ROBINSON:

You want an even better example of that, Mike? Look at Aurora.

They’re the second biggest cannabis grower in Canada.

They did a private offering for just five cents a share.

C_10

Since going public, their stock has been as high as $16.24.

If you put in $10,000 when they were still private, you could have cashed out for as much as $3.2 million.

C_11

If you had waited until they were public to invest that same $10,000, it’d only be worth around $200,000.

C_12

That means you could have made almost $3 million more by investing when they were still a startup.

MIKE WARD:

This really opens up a whole new world for everyday folks.

Without starting your own business, there’s really no other way we see to build that kind of wealth.

Of course, not every one of these deals pans out; some will make it, while others won’t. So it’s important not to risk more than you can afford.

However…

Just one big-winning private deal can make you hundreds of thousands… if not millions of dollars richer.

Okay, Michael, let’s get to the heart of the matter… and why we’ve come together today.

Most folks here have heard about GW Pharmaceuticals.

They recently made international news with their newly approved drug for seizures, Epidiolex.

Their public stock has been up as much as 1,789%.

C_13

But most folks don’t know that GW offered a handful of investors shares when they were still a private startup.

MICHAEL ROBINSON:

A famous musician, a professional athlete, and a few high-powered VCs went in on that deal. But so did some everyday investors who just believed in GW’s vision.

This was at around a $70 million valuation.

Today, they’re worth over $4.8 billion…

C_14

We’re talking about a gain estimated at 6,571%.

MIKE WARD:

Ok, Michael.

That’s the equivalent of turning $10,000 into over $657,000.

C_15

And that’s exactly why we’re here today.

We’re about to hear from a company in cannabis-based pharmaceuticals.

Only this company could be on track to triple – or even quadruple – what GW has already proven can be done.

So folks, you’re going to want to pay very close attention to this.

AvtarImage

MICHAEL ROBINSON:

Absolutely, Mike.

The startup founder we’re hearing from today is Dr. Avtar Dhillon.

Avtar has worked in the pharmaceutical industry for more than 30 years.

He’s been chairman of five public life sciences companies.

Most notably, he led the turnaround of Inovio Pharmaceuticals, driving their revenue up over 5,400%.

C_15

And he’s already taken a company public in the health and cannabis space.

Early investors in that company could have already seen peak gains of 7,070% in under two years.

MIKE WARD:

So here’s what we’re going to do.

You’ve been very involved with private companies like this.

You’ve already helped investors make millions of dollars...

And you’ve made millions for yourself as well.

So we’re going to let Avtar – Dr. Dhillon – present his case for the company.

But at certain points, I’m going to stop the tape and have you analyze what he’s saying.

My goal is to show folks not just how to prepare for this opportunity…but to show them how an experienced investor analyzes opportunities like this for themselves.

I want folks to be able to see this deal through your eyes.

Sound good?

MICHAEL ROBINSON:

Let’s do it, Mike.

MIKE WARD:

Great.

Here’s Dr. Avtar Dhillon…

Hello, my name is Avtar Dhillon.

I’m the Founder and Chairman of Emerald Health Pharmaceuticals.

We are a private company based in San Diego, California.

And we’re currently raising a financing round under SEC’s regulation A+.

So this presentation is going to contain some forward-looking statements based on our management’s assumptions and beliefs.

Today, I’m going to show you why we believe Emerald Health Pharmaceuticals is helping to lead a fundamental shift in medicine.

As you’ll see, our initial drugs target a combined $38 billion market. These are diseases with huge unmet needs.

And as our pipeline of new drugs progresses, we could reach markets that are much bigger than that.

Let me show you why.

Take a look at this image.

GA_01

There’s a good chance you know most of these systems.

That’s because for the past 50 years, this is what medical science focused on treating.

Cardiologists treat the cardiovascular system.

Neurologists treat the nervous system.

Gastroenterologists treat the digestive system.

The respiratory, immune, reproductive, and endocrine systems all have their own specialized treatments and medications.

But what if one vital body system was entirely ignored?

What if many of today’s “incurable” diseases were actually only “incurable” because we’ve been entirely neglecting this system?

Today, I’m going to show you evidence that this may be exactly what happened.

Now if this system is so important, why did doctors ignore it for so long?

Because they didn’t know it existed.

GA_01b

It’s called the endocannabinoid system – or ECS – and it wasn’t discovered until 1992.

Since its discovery, scientists have made rapid progress understanding it. And the more we learn about it, the more critical it appears to be.

GA_02

In fact, we now know the ECS plays an important role in most major functions of the body.

GA_03

It’s involved in motor control and coordination…

  • Memory and learning...
  • Anxiety and stress...
  • Reward and addiction…
  • And a lot more.

Very quickly, let me explain how it works.

GA_04

Your body naturally produces chemicals known as cannabinoids.

GA_05

These cannabinoids keep your body healthy and balanced by interacting with special receptors in your body.

You can think of these cannabinoids as “keys” and the receptors as “keyholes.”

There are two types of keyholes that work with cannabinoids.

CB1 and CB2.

GA_06

CB1 receptors are mostly in the brain and central nervous system.

CB2 receptors are mostly in the immune system.

When your body is under extreme stress… when there is a lot of inflammation present… something very interesting starts to happen.

Your immune cells produce extra CB2 receptors.

That means they start demanding more cannabinoids than your body can naturally make.

Luckily, nature provided a solution.

Cannabinoids are also found in cannabis.

When you give your body enough of the right cannabinoid “keys” to fit in these “keyholes,” it can ease inflammation.

GA_08

And unlike many of today’s anti-inflammatory drugs, it does this without suppressing your immune system.

Since so many diseases are linked to chronic inflammation, this may be the reason medical cannabis has shown such a wide variety of benefits.

However, for every study that shows promise with cannabis, there’s another that does not.

Why is that?

The answer is simple.

The cannabinoids found in cannabis are NOT perfectly shaped keys for our CB1 and CB2 receptors.

They’re close enough to have some effect for some people. But they don’t always fit perfectly.

That’s why we started Emerald Health Pharmaceuticals.

We’ve taken the natural structure of two non-psychoactive molecules from the cannabis plant – CBD and CBG – and created synthetic versions.

GA_09

Then, using cutting-edge biotechnology, our team modified them again.

GA_10

These synthetic versions are far superior to natural versions.

They’re engineered to fit much better into the CB receptors.

That means they can have a more powerful effect.

GA_11

And they’ve been given a structure that allows them to target other important receptors as well.

This allows us to focus on treating – and potentially even curing diseases that have no current effective treatments.

We are currently in the clinical stage of development.

GA_12

We have a big competitive advantage with 8 patents granted and 26 pending. These give us protection up to 2037.

GA_13

We have an incredibly strong team with decades of pharmaceutical experience. We have two of the global leaders in cannabis research, Drs. Eduardo Munoz and Giovanni Appendino.

This Regulation A+ financing allows us to raise up to $50 million at $6 per share.

Today I’m going to show you our top two drugs. And we’ll discuss how they’re going to reach a nearly $38 billion market

MIKE WARD:

We’re going to get back to Avtar in just a second.

But I want to dig into a couple of points he made.

First of all, he said this is a Regulation A+ deal. That means it’s basically open to anyone, right?

MICHAEL ROBINSON:

That’s right. There are a few different ways private companies can offer shares to investors.

A lot of companies choose Regulation D deals. But Regulation D requires investors to be accredited.

So you need to make $200,000 a year – bump that to $300,000 if you’re married.

Or you need a net worth over $1 million, not counting the value of your house.

Regulation A+ is more flexible.

Anyone can participate in this. You do not need to be accredited.

So this can be a great way for anyone to get started in this arena.

MIKE WARD:

You could invest $10,000… or $5,000…

Or let’s say you start with just $1,000…

If Emerald keeps pace with what GW Pharmaceuticals did… that $1,000 could grow to over $65,000.

C_17

Now let’s talk about the endocannabinoid system.

Because this really blew my mind the first time I heard of it...

MICHAEL ROBINSON:

As it should, Mike.

I believe the discovery of the endocannabinoid system will win a Nobel Prize someday.

It exposes a major medical blind spot. And it’s opening up a whole new world of potential cures.

MIKE WARD:

We’ve been hearing about inflammation for the past 20 years.

Studies have come out saying inflammation is the real cause of heart disease. It may be the real cause of Alzheimer’s, diabetes, cancer – everything.

A decade ago, Harvard Medical School said inflammation may be the “unifying theory of disease.”

Unifying theory of disease.
HARVARD MEDICAL SCHOOL

And now it turns out we just discovered a major body system that can eliminate it.

MICHAEL ROBINSON:

Avtar called this a fundamental shift in medicine. And he’s right.

Until now, doctors have basically been trying to bring down inflammation by brute force. That causes all kinds of nasty side effects.

Cannabinoids can do the same thing by working with your body’s natural system.

So the side effects are almost non-existent.

MIKE WARD:

Avtar is going to get into the results next. So I think folks are going to get a good sense of that.

But one thing that occurred to me when watching this…

I think a lot of people are going to wonder…

Why use a synthetic version? Why not just use natural CBD?

MICHAEL ROBINSON:

I asked Avtar that same question.

It basically comes down to two things.

First, supply.

If you’re relying on plants, a lot of things can go wrong… like crop failure .

One company that I can’t mention here, lost 15 tons of cannabis to crop failure.

There’s also a risk that one crop might be slightly different quality than the last.

In a big pharmaceutical company, you just can’t take that kind of risk.

With synthetic CBD, you can create an endless supply, with full quality control.

So you get the exact same molecule – the exact same drug - every single time no matter what.

That’s what the FDA requires.

Second, there’s the business reason. You can’t patent a natural molecule. But you can patent a synthetic one.

With FDA approval, it gives Emerald a monopoly on a multibillion-dollar market.

This is the holy grail.

If you get there, you almost can’t fail.

So the next thing I have to know is, how well does the treatment work?

MIKE WARD:

Let’s look into that now.

Let’s go back to Avtar…

The first drug we are developing is EHP 101.

GA_14

EHP 101 is in clinical trials for the treatment of Multiple Sclerosis.

GA_15

This is a serious and devastating disease.

MS affects about 2.3 million people worldwide. In financial terms, it’s projected to be a $27.4 billion market by 2025.

The current treatment options are, frankly, terrible.

Today, doctors treat MS with medicines that suppress the immune system and with toxic drugs like chemotherapy.

And there’s never been a drug that comes close to curing it.

That’s because it’s a demyelinating, central nervous system disorder.

GA_16

What does that mean?

Well, our nerves are protected by what’s called a myelin sheath.

In folks with MS, the immune system begins attacking that protective covering.

This eventually leaves multiple points of sclerosis. That means multiple scars on the nerves.

This causes a lot of pain, weakness, and muscle spasms.

It also leads to fatigue, depression, and anxiety.

It can cause visual problems.

And on top of that, there are painful digestive issues associated with the disease.

GA_17

Up until now, the best doctors could do was manage symptoms.

No one has been able to develop a drug that could restore the myelin sheath.

Which is why we’re so excited that it appears that EHP 101 may be able to rebuild myelin.

That means there’s a chance EHP 101 can not only manage symptoms of MS better than any drug on the market…It may actually be able to cure the disease.

This is a huge step forward.

Even the National Multiple Sclerosis Society said that “Repairing myelin was just a dream just a few years ago. Today, it holds significant promise as a strategy… for reducing or stopping MS.”

Here’s why EHP 101 could be such a powerful treatment for MS.

We designed the molecule to target not one, but three of the receptors associated with MS.

GA_18

It targets the CB2 receptors associated with the inflammatory aspect of the disease.

It targets the PPARG receptors associated with both the inflammatory and neuro-degenerative aspects of the disease.

And it targets the HIF receptor associated with the demyelinating aspect of the disease.

That makes it a uniquely powerful treatment. And our animal models prove that point.

Take a look at this...

This is an animal with full-blown MS.

BRoll_02

His paws are dragging. He’s moving slowly, basically dragging himself around.

He’s probably not able to stand up because his nerves are almost fully demyelinated.

It’s not pleasant.

Now look at this animal.

BRoll_03

He once had the exact same symptoms.

But we treated him with EHP 101. As you can see, he’s energetic and bouncing around. There’s no sign of pain.

In fact, there’s no evidence of MS at all.

After the treatment, his nerves were fully remyelinated.

If we can replicate this in humans, it's the holy grail. It's a massive opportunity.

Remember, MS is projected to be a $27.3 billion market by 2025.

So, if we can prove even a fraction of the results we saw in our animal trials, this is a breakthrough for patients.

And it’s a multibillion-dollar revenue stream for us.

GA_19

We’re currently wrapping up our Phase 1 clinical trial.

Phase 1 trials are simply intended to prove the drug is safe to use for humans at different doses.

In our animal models, the drug didn’t show any toxicity until we reached 552 milligrams per kilogram.

That dose is 10,000 times more than we’d ever use in humans. So, we believe the drug is very, very safe.

We hope to prove that in our current Phase 1.

And we’re confident enough based on early results that we’re actively preparing our Phase 2 trial to start later this year.

GA_21

That’s where the rubber meets the road in proving effectiveness in humans.

Now, even if MS were the only effective use for EHP 101, it would be a very exciting drug.

But our early tests have shown it’s effective for another disease - Scleroderma.

Scleroderma is another autoimmune disease.

GA_22

That means the immune system starts attacking its own body.

In scleroderma, that causes scarring in skin, muscles, and lungs.

This disease affects about 50,000 Americans.

GA_22

It kills as many as half of its patients within 10 years of a diagnosis.

So it’s a major problem. And the treatment options are pretty thin.

In fact, there isn’t a single drug approved specifically for scleroderma right now.

We believe we could be the first.

The same way EHP 101 can calm the immune system and help eliminate scar tissue for MS, we think it can work for scleroderma.

Again, the CB2, PPARG and HIF pathways have been studied extensively for scleroderma.

EHP 101 is the first drug that targets all three.

And based on our animal studies, it looks like this could be another very successful application.

This is a close-up of tissue affected by scleroderma.

GA_24

Each of those circles you see is a fibrosis. That’s scar tissue.

Now look at this image of the same tissue, but also treated with EHP 101.

GA_24

Instead of six incidents of fibrosis, there’s only one.

That’s a massive reduction in scar tissue.

These results were published in Nature’s Scientific Reports journal.

GA_25

This study earned EHP 101 an orphan drug designation both in the United States and in Europe.

GA_25

That means we have an easier path through the regulatory approval process.

And because EHP 101 is already undergoing a Phase 1 clinical trial for MS, we expect to be able to move straight into Phase 2 trials as soon as our Phase 1 is completed.

Remember, Scleroderma is a relatively rare condition.

Only around 50,000 Americans a year contract it.

But it is devastating and very often lethal.

And no other treatments effectively combat it.

So, because it’s been given an orphan drug designation, if approved, we’ll have seven years of market exclusivity.

That means we’re hoping to capture the lion’s share of the soon-to-be $3.7 billion market.

Combine that with the $27.4 billion MS market, and you really start to grasp the opportunity we have with our synthetic cannabis-based drugs.

MIKE WARD:

There are a couple things I want to point out here.

First of all, that video of the MS cure is incredible.

Can you imagine how the market will react when we to start seeing videos of people suddenly walking normally again… speaking normally… standing up without pain for the first time in years?

MICHAEL ROBINSON:

Absolutely. There’s a lot of pain and suffering in the world. Not even Bill Gates can eliminate it all.

But we can do our part.

Multiple Sclerosis affects 2.3 million people.

Meaning EHP-101 could have an enormous impact.

It could reduce a ton of suffering in the world.

That’s what I love about startups.

We have an opportunity to help Emerald get it out to the world.

MIKE WARD:

And the commercial side is huge.

MS is projected to be a $27 billion market.

If Emerald grows to match that market, it can jump up over 54,000%.

And that’s obviously a big thing to look at as an investor in this kind of deal.

Is there a market that needs the product?

MICHAEL ROBINSON:

Clearly, the answer is yes for both MS and scleroderma.

Over two million people are desperate for a cure.

They’re projected to spend $30 billion a year on treatments.

Now it’s impossible to say exactly how much of either of these markets Emerald could capture.

However, we have some benchmarks we can look at.

Historically, any kind of major MS discovery drives incredible growth.

For example, in 2014, Biogen published a study about a new drug they developed that relieves just a few MS symptoms.

It helped drive their market cap up $33 billion.

C_18

Compare that kind of mild symptom relief Biogen could offer with Emerald’s potential cure.

You can only imagine how big Emerald could grow...

MIKE WARD:

Michael, let’s compare it to another company.

You mentioned earlier that GW Pharmaceutical’s private investors could be up as much as 6,571%.

That’s based largely on their CBD treatment for epilepsy: Epidiolex.

So how does EHP 101 compare to Epidiolex?

MICHAEL ROBINSON:

There are a couple things I’ll point out about GW.

First, epilepsy is a bigger market than scleroderma…

But MS is a much bigger market than epilepsy.

C_20

So Emerald has a higher ceiling – just based on the conditions they’re treating.

The other important thing to note about Epidiolex – it uses a natural CBD molecule.

So they have some potential supply and quality issues.

The fact that it’s natural also means GW can’t fully protect it with patents.

You can expect somebody to develop a similar drug and steal some of their market share.

EHP 101 is a synthetic CBD molecule.

So not only has Emerald been able to make it more powerful – to the point of potentially curing MS and scleroderma – they also have the molecule fully patented.

Meaning…

With EHP 101, Emerald could have a 30-year monopoly on the cure for MS.

That’s really exciting for early investors.

MIKE WARD:

And Emerald isn’t resting on their laurels with this first drug. They have even more drugs in their pipeline.

In fact, let’s go back to Avtar and hear about their second drug….

Our second drug is EHP 102.

GA_27

First, a little background…

One of the more interesting functions of the endocannabinoid system is its role in the brain.

Cannabinoids are a critical part of early brain development.

And they remain important for our entire lives.

Studies show that disruptions in the endocannabinoid system can accelerate brain aging.

It can speed up the development of Alzheimer’s, Parkinson’s, and other similar conditions.

That’s why one of the most exciting fields of study is using cannabinoids to improve and potentially cure serious brain diseases.

GA_29

That’s what we’re hoping to accomplish with EHP 102.

This is a little different than EHP 101.

EHP 102 is based on CBG.

CBG is better known as the “stem cell of cannabinoids.”

That’s because – just like human stem cells form into every other type of cell in the body – CBG forms into the rest of the cannabinoids.

The most interesting part of CBG is that it appears to be strongly neuroprotective. That means it’s able to slow down certain symptoms of aging in the brain.

Even more promising, it appears to be neuro-regenerative.

So it may be able to reverse brain aging… even to the point of curing some diseases.

Just like with CBD for our first drug, our scientific team synthetically recreates the chemical structure for CBG.

From there, we enhance it further to target an extra receptor.

The result is our patented molecule, EHP 102.

We’re currently studying EHP 102 for two diseases.

The first is Parkinson’s disease.

Parkinson’s is a disease that causes serious tremors, mainly in the hands, and can cause walking and balance problems.

There are about 10 million people suffering from this disease worldwide.

There’s no known cure.

In fact, there’s not even a “standard” treatment for Parkinson’s.

So doctors and patients are both desperately looking for more treatment options.

And we believe EHP 102 can fill that need.

You see, Parkinson’s is a disease where inflammation damages neurons in your brain.

GA_31

This damage stops the brain from producing enough dopamine.

Most people know about the effects dopamine has on your mood. However, it’s also critical for transmitting signals from your brain to your muscles.

So if you can reduce inflammation at the same time you slow down – or even reverse the damage to the neurons – it can be a lifesaver for Parkinson’s victims.

So that’s what we wanted to look at.

What effect does EHP 102 have on inflammation and neurons?

Well, we’re still in the early stages, but it looks incredibly promising.

We published our initial study last year in the Journal of Neuroinflammation.

GA_32

Our scientists tested EHP 102’s effectiveness for mice with Parkinson’s.

GA_33

First, we found it reduces inflammation.

That’s important because inflammation in the brain has a cascade of side effects.

Second, it prevents dopaminergic neuronal loss.

These first two findings mean EHP 102 could dramatically slow disease progression…

However, the third finding is how we really know it’s working.

EHP 102 actually helps improve tremors, coordination, and balance.

We believe – based on these early results – that this could soon be a very valuable treatment option for folks with Parkinson’s.

There are almost NO other treatments that attack the root cause of Parkinson’s. And none of the current treatments address the endocannabinoid system.

This is projected to be a $5.24 billion market.

And we’re moving rapidly through our pre-clinical trials to start testing this treatment in people.

GA_34

There’s another indication that could speed up the approval process for EHP 102.

It also looks like it’s effective for Huntington’s disease.

GA_35

That’s allowed us to get another orphan drug designation.

Huntington’s is a rare genetic brain disease that affects more than 30,000 Americans.

It causes neurons in different areas to die off.

This leads to uncontrolled movements…

Abnormal body postures…

And changes in behavior, emotion, and judgment.

Eventually, it leads to impaired coordination, slurred speech, and difficulty feeding and swallowing.

Symptoms get continually worse until they become fatal

Well, the same neuroprotective effects that make EHP 102 so effective for Parkinson’s also make it promising for Huntington’s.

GA_36

Our scientific team tested this on two different models for Huntington’s.

You can see here, EHP 102 is effective for both.

GA_37

Using this drug improved motor function and clinical scores.

That’s extremely exciting for us.

That means EHP 102 isn’t just slowing down the progression of the disease…

It’s actually helping regrow neurons in the brain.

Now, because Huntington’s is a genetic disease, there is no cure.

Our hope is EHP-102 can protect neurons and potentially even regrow them in our human trials…

If it works as well as it does in other animals, we can dramatically improve the symptoms, maybe even to the point where the disease isn’t fatal.

The market for Huntington’s is projected to hit $2.4 billion in the next five years.

And because of our orphan drug status, we’ll have seven years of market exclusivity if approved.

MIKE WARD:

EHP 102 sounds like it could be a real breakthrough for people with Parkinson’s and Huntington’s.

Now those markets are both smaller than MS.

C_21A

But they’re still a combined $7.6 billion.

C_21B

That means they’re 15,000% bigger than Emerald’s current $50 million offering.

Michael, if someone was considering making an investment, what would stand out to you?

MICHAEL ROBINSON:

There are a couple things here.

First, just the fact that they have a second drug at all is a very good sign. A lot of companies will raise money or go public with just one product.

That’s what GW Pharmaceuticals did, and it worked out pretty well for them.

So having a second product so far along is a great sign.

I also like that it’s CBG, not just another CBD drug.

MIKE WARD:

That stood out to me, too.

Most folks only know about THC and CBD.

THC is the cannabinoid that creates that “high” feeling. And CBD is the most widely known for its health benefits.

But there are at least 36 different cannabinoids in the plant.

And you don’t hear a lot about the others.

MICHAEL ROBINSON:

That highlights how new this industry is.

And it shows how far ahead of everyone else Emerald really is.

CBG research has really been heating up the last few years.

And it could prove to be even more powerful than CBD.

Especially for the brain.

Avtar talked about the applications for their CBG-based drug on Parkinson’s and Huntington’s… combined, that’s a projected $7.6 billion market.

But CBG is also being looked at for much more common diseases.

A big one here is Alzheimer’s – that’s going to be a $14.8 billion market.

It’s also being looked at to treat colon cancer.

That’s projected to be an $11 billion market.

C_22

Emerald is way ahead of the curve on their research.

So I wouldn’t be surprised if they were the ones to release the breakthrough drugs in any of those markets.

MIKE WARD:

So just to sum up where we are so far…

Emerald has two promising drugs with the proven ability to address MS, scleroderma, Parkinson’s disease, and Huntington’s disease.

Combined, that’s a projected market of around $38 billion dollars.

GA_23

On top of that, based on the endocannabinoid research they’re doing…

They could release breakthroughs for other major diseases.

What else would you typically want to know before investing, Michael?

MICHAEL ROBINSON:

The only big question left is who’s on their team?

A weak team can really hold back a good company.

Luckily, we know that’s not the case with Avtar at the helm. He proved he’s an elite CEO with Inovio Pharmaceuticals.

He literally increased their revenue over 5,400%.

So the only thing I’m asking myself at this point is what does the team around him look like?

And in this case…

The opportunity we’re bringing you today has a collection of all-stars at its back.

You couldn’t find a better suited team, Mike.

MIKE WARD:

I couldn’t agree more, Michael.

However, let’s have Avtar finish his presentation, then we can talk about them…

Emerald Health Pharmaceuticals is run by a very experienced team.

Dr. Jim DeMesa is our CEO.

Jim has both a medical degree and an MBA.

GA_38a

He has 29 years of experience in the pharmaceutical industry, and he’s spent 15 years as the CEO of public biotech companies.

Our Chief Scientific Officer is Dr. Eduardo Munoz.

Dr. Munoz is a professor of immunology and one of the leading cannabis researchers in the world.

GA_38b

His work has been cited over 5,000 times.

That makes him one of the most influential researchers – not just in cannabis, but in any medical field.

Dr. Giovanni Appendino is an active contributor and a member of our Scientific Advisory Board.

GA_38c

Dr. Appendino is a professor of Pharmaceutical Chemistry.

He’s a pioneer in cannabis research, and he personally holds multiple cannabinoid patents.

Dr. Rao Movva is another one of our advisors.

GA_38d

Dr. Movva has 30 years of experience in drug discovery and development.

He helped discover the TOR pathways, which is considered a medical breakthrough.

And he’s a Novartis Distinguished Scientist – one of the highest awards in the pharmaceutical industry.

Our clinical advisors on MS and Scleroderma are literally among the top five clinicians in the world in their respective fields.

GA_39

This is the cannabis-medicine dream team.

These gentlemen could work with almost any pharmaceutical company in the world, but they all choose to work with Emerald.

And they’re a major reason why Emerald Health Pharmaceuticals could lead a healthcare revolution.

The initial markets we’re targeting are huge. They’re projected to reach about $38 billion.

And we have a number of peer companies with significant valuations.

The biggest is GW Pharmaceuticals.

GA_41

They have an FDA-approved drug that uses a natural CBD extract. It’s used to treat seizures.

And even without being able to patent the CBD molecule they’re using, they have a $4.6 billion market cap.

Corbus Pharmaceuticals has a synthetic CBD that they’re using to treat Systemic Sclerosis and Dermatomyositis.

They’re in clinical trials, and they have a market cap of $422 million.

GA_42

We believe we’re well-positioned in the market.

We have outstanding patent protection. We’ve been granted eight patents and we have another 26 pending. That gives us protection until 2037 for multiple diseases.

So today, we’re raising money at $6 per share on a first-come, first-served basis. This money will fund our clinical trials, research and development, and general working capital.

Look, I’ve been involved in both the cannabis and pharmaceutical industry for the past 30 years.

I’ve taken companies public several times.

I’ve worked as the CEO of a major public pharmaceutical company - Inovio.

I’ve seen a lot.

And I’ve rarely seen a company positioned as well for fast growth as we are at Emerald Health Pharmaceuticals.

We could help a lot of people with serious diseases who desperately need better treatment options.

And hopefully, we’re going to make a lot of money doing it.

I hope to have you on board.

MIKE WARD:

That was Avtar Dhillon – the chairman of Emerald Health Pharmaceuticals.

He’s sitting on a potential cure for four “incurable” diseases.

Michael, you almost never see a pharmaceutical company with four potential cures.

MICHAEL ROBINSON:

That’s why I think the Endocannabinoid system discovery is going to win a Nobel prize.

Emerald is way ahead of the market in MS, Scleroderma, Parkinson’s and Huntington’s.

So they could capture the lion’s share of that projected $38 billion market.

But that’s only one thing I like about this company.

I also love the team.

Avtar’s record speaks for itself...

  • He took Inovio Pharmaceuticals from $10 million to $500 million...
  • He’s chairman, or on the board, of some of the most successful health companies in the U.S. and Canada...
  • And I really like what he’s doing with the Emerald brand.
C_24

Emerald Health Pharmaceuticals is a company under Emerald Health Sciences.

And Avtar has already taken another company public under that brand…

Emerald Health Therapeutics.

Early investors in Emerald Health Therapeutics could have already seen peak gains of 7,070% in under two years.

C_24

That’s enough to grow $10,000 to over $700,000.

C_25

And he did that with a team that’s not even as impressive as the one we’re looking at with this venture.

They have three of the world’s top experts on cannabinoids. These are the guys creating and testing their products.

And they have an awesome CEO in Jim DeMesa, who has run big pharmaceutical companies before.

GA_02

They have literally the best advisory team they could get…

MIKE WARD:

Alright, great team, and great product. The next question here is about the price.

They’re currently selling shares for $6 each.

Michael, what do you think of that valuation?

MICHAEL ROBINSON:

I like it a lot.

That’s a $50 million investment cap.

You have to look the few comparable companies in this space.

C_26

Zynerba Pharmaceuticals is in preclinical trials for a synthetic CBD and THC molecule for treating pain and epilepsy.

They are worth $88 million dollars.

CV Sciences is still in preclinical trials with their CBD-based smoking cessation drug.

They’re worth $459 million.

So from where Emerald is sitting, I actually think they’re undervalued.

MIKE WARD:

So what’s the next step for the company?

How big could they get?

MICHAEL ROBINSON:

Well, we know that Avtar likes to take his companies public.

So that’s the most likely route for Emerald.

They would probably do that IPO at the end of this year or early next.

We know they’re trying to start their Phase 2 trials this year.

If they finish Phase 2 trials by their IPO, they’re going to be worth $150 – $250 million.

So by the end of the year, with their IPO, an investment today could already be up 400% or 500%.

MIKE WARD:

That’s already an impressive gain.

That’s the equivalent of turning a $1,000 investment into $4,000 or $5,000.

A $10,000 investment into $40,000 or $50,000.

But there’s one point I want to go back to. You touched on their competition a second ago.

Do any of their competitors worry you?

MICHAEL ROBINSON:

I look at their competition as a positive.

I would actually worry more if there were no competitors at all. That’s usually a sign that there’s not a big enough market.

With this market, there’s enough competition, but not too much. And it’s also a good sign that their competitors are making investors money.

Look at Corbus Pharmaceuticals. That’s probably Emerald’s closest competition.

They have a synthetic CBD molecule that treats systemic sclerosis.

Corbus did a private financing round in December of 2013.

At that point, one investor put in $20,000.

C_30

By the time they went public in April of 2015, his shares were worth $3.1 million.

That’s what I like to see.

MIKE WARD:

Now, one thing we’ve seen in the past is a smaller startup with a drug breakthrough getting bought out by a bigger company.

What would that mean for investors if that happens with Emerald?

MICHAEL ROBINSON:

It’s usually good news for their investors.

Look at what happened with ICC Labs.

They were a Canadian company that developed a method for extracting cannabinoids.

They did a private offering back in 2016, before their IPO.

Then last year they were acquired by Aurora, one of the biggest players in the cannabis industry.

That could have turned into a 2,686% profit for their private investors.

Nothing to complain about there.

MIKE WARD:

And if they don’t accept any acquisition offers?

MICHAEL ROBINSON:

Then they’d have a longer road.

But with their treatments, they could be up there with the biggest pharmaceutical companies in the world someday.

Our team did an analysis of Emerald’s potential future valuation.

Their minimum success case – if one of their drugs gets just a 10% market share – that makes Emerald worth $1.8 billion.

So starting from $50 million… that’s the potential for 3,600% growth on the low end.

That’s like turning $10,000 into $360,000.

C_33

If they end up actually curing MS – a complete success case – our team puts their valuation as high as $52.5 billion.

C_32b

105,000% bigger than they are today.

That’s enough to turn a $10,000 investment into $10.5 million.

That’s how you earn private island kind of money.

Think about that, Mike.

MIKE WARD:

With Emerald’s team…

With Avtar and their scientific board…

I don’t think there’s anything stopping them from reaching that $52.5 billion mark.

So Michael, let’s get into the details.

Emerald Health Pharmaceuticals is doing an offering up to $50 million.

As Avtar said in his presentation, they’re selling shares for $6 each.

Now because this is a Regulation A+ deal, there are some restrictions.

MICHAEL ROBINSON:

First, let me tell you that most deals like this are for accredited investors.

So only millionaires and people with very high incomes can access them.

This is one of those rare deals that anyone can get into.

The only restriction is non-accredited investors can only invest 10% of their total income, or net worth.

MIKE WARD:

That means if you make $100,000 a year – or have a total net worth of $100,000 – you can put in $10,000.

And this is one of the only opportunities for everyday investors to turn that $10,000 into $10.5 million…

MICHAEL ROBINSON:

Acreage holdings – that’s the company our friend John Boehner is involved with – they sold shares for $6.20 four months before their November 2018 IPO.

So those private investors were already up 226% at the IPO.

Let’s say Acreage’s stock runs up to $100.

Folks who invested at their IPO would be up around 406%.

C_36B

That’s pretty good.

But the folks who got in four months earlier, when Acreage was still private, would be up 1,512%.

On a $10,000 investment, that’s the difference between $50,000 and $151,200.

C_37

In other words, you’d make $110,000 more as a private investor.

MIKE WARD:

And with Emerald, once the company decides to go public, there’s no limit on how high it can go.

If they reach a $4.8 billion market cap, a simple $10,000 stake would be worth $920,000.

If it goes to the maximum $52.5 billion… it’s hard to even comprehend what $10.5 million dollars would be like.

C_38

And we know it’s possible to make millions on these kinds of deals.

C_39

A $10,000 stake in Corbus Pharmaceuticals’ first private offering would have been worth $1.6 million at their IPO.

A $10,000 stake in Canopy Growth’s first private offering would have peaked at $1.2 million.

$10,000 in Aurora’s first private offering would have peaked at $3.2 million.

This is the kind of opportunity that folks dream about.

This is the only way to buy private shares of Emerald Health Pharmaceuticals right now.

And here’s the best part.

As amazing as this opportunity is…

Think about this…

What if you could access deals like this 4… 5…. 6 times a year?

That’s what I want to talk about now.

The cannabis sector is growing faster than any other industry in the world. It’s projected to grow from $10.8 billion to over $1 trillion.

And as more and more states legalize, thousands of entrepreneurs launch new startups.

As the #1 resource for cannabis investors, hundreds of them come to us every year.

And we know that only a small number of these deals have the potential to be blockbuster, multi-billion dollar companies.

We want to makes sure we get those few, top-tier deals, in front a select group of our readers.

Because we know…

These kinds of companies are the only way to turn a small stake into potentially millions of dollars.

Our mission here at the National Institute for Cannabis Investors is to show average folks new ways to tap into the unbelievable growth in this industry.

That’s why we’ve created a brand-new research service.

It’s called the Cannabis Venture Syndicate.

We’re gathering a small group of members together and giving them all the research, fact finding and information they need for their chance to invest in at least four to six private cannabis companies every year…

Starting with Emerald Health Pharmaceuticals.

Now, there’s a strict limit on the number of people who can participate in these deals.

We want to make sure everyone who joins our service could get the chance to invest if they want.

And we expect to fill up this first membership class in just a day or two.

Because without a doubt, the biggest returns can come from this kind of early-stage investing.

So, Michael, can you talk a little bit about the advantages of joining a service like this?

MICHAEL ROBINSON:

The problem is, with private investing, you usually have to know somebody to get in on these deals.

So for the average Joe, it can be really difficult to find deals.

On the flip side, if you’re already a successful private investor, you start drowning in deals.

Now even with the deals that look like obvious winners, I’m not going to want to invest all $5 million, $10 million, or $20 million they’re trying to raise.

MIKE WARD:

That’s right.

Emerald is a speculative play and is heavy in development, so it’s a pre-revenue company.

It’s always important to remember not to risk too much on any single investment, no matter what kind of investment it is.

MICHAEL ROBINSON:

That’s just common sense.

That’s why a few years ago, some of the most successful private investors started forming “syndicates.”

Here’s how a normal syndicate works.

The lead – that’s the investor finding these deals – gathers a group of folks interested in investing, but don’t have the connections.

He vets all the opportunities coming in, then he picks the best deals and presents them to his syndicate.

He explains why he’s investing, and the rest of the syndicate members can decide whether they want to invest with him or not.

That way, the company can make one pitch to a syndicate, and raise their whole round in one shot.

The lead investors get even more deals because they can bring more capital to the table.

And the members of the syndicates get access to deals they never would have seen if they hadn’t been in the syndicate.

Then, after they do a couple deals, the syndicate members start to become industry insiders themselves.

They start connecting with fellow investors.

I know folks who have gotten tours of movie sets and backstage passes to concerts, just because they invested alongside movie stars and world-famous musicians.

Now this research service doesn’t operate the way traditional syndicates do. I think the model we’ve set up is even better, Mike.

There’s all the same upside – you can make just as much money…

And because our team is not investing personally, we can provide totally unbiased research on every deal we present.

In traditional syndicates, you never know if the lead investor has a conflict of interest.

MIKE WARD:

Now Michael, you’ve been doing this for years.

But for most folks, this is going to be their first time considering an investment in a private company.

So we want to make sure they get up to speed as fast as possible.

WYG_01

Which is why we’ve put together the Private Investing Primer.

This is a short book with the 12 most important lessons you need to know to start investing in private companies.

It covers everything from building a deal flow, analyzing a pitch, understanding valuation and deal structure…

It reviews the different kinds of deals and what kinds of investors can participate in each.

So it could be a Regulation A+ or crowdfunded… these are the types of deals anyone with any income or net worth can participate in…

Or it could be Regulation D that only accepts accredited investors.

There’s a chapter that reviews the different rounds of private financing and their advantages and drawbacks.

So if you want to know the difference between a seed round, an angel round, and a series A, you can flip to this chapter.

Plus, it has a glossary of terms.

So if a CEO in one of their pitches uses a term like “burn rate” or “pro rata” or “dilution,” you can just flip to that glossary and you’ll know exactly what they’re talking about.

MICHAEL ROBINSON:

This is crucial, Mike.

Back when I was just starting out, I would have loved a resource like this.

I’d probably have twice as much money as I do now.

It gives our readers a serious leg-up on the competition.

MIKE WARD:

You’re absolutely right.

Cannabis Venture Syndicate is built so both folks brand-new to investing in startups – as well as insiders – get the most out of it.

Whenever you or our team finds a deal, the first thing we do is pretty much what we just did.

You’re going to get a pitch deck from the company and a video of an executive walking you through it.

That’s what you saw with Avtar earlier.

WYG_02

A pitch deck is just a presentation that lays out the company’s case to potential investors.

A good pitch deck tells a compelling story…

  • It lays out what the company does...
  • Who is on their team...
  • And why they believe they’re going to deliver a huge return for investors.

However, this pitch deck is just the starting point.

If you’re thinking about investing $10,000 or more in a company, you need more than just a good story.

So you also get a comprehensive due diligence package.

MICHAEL ROBINSON:

I just want to point out what a huge advantage this is for members.

Most folks who invest in private companies – they’re flying blind.

They don’t really know how to read a financial statement.

They don’t have any advanced modeling to predict future revenue under different market conditions.

And they have no way of doing a real competitive analysis.

But our members will have experts in all of these areas already on their team.

MIKE WARD:

Our team breaks everything down.

We explain their cashflow and burn rate.

WYG_03

We do a revenue and valuation growth projection.

And we give you a thorough analysis of their competition.

Going through this due diligence package, you’ll understand the company and why we project it could return 2,000%... 5,000%... even 10,000%, or more.

MICHAEL ROBINSON:

I’ll tell you Mike, I wish I would have had a team like this when I was new.

Which is why this next step is so important.

Once I’ve seen the company’s pitch and fully analyzed the due diligence, I write up a deal memo.

I started doing this a few years ago and it’s one of the best habits I have.

This memo is pretty straight forward, but it’s absolutely critical for my decision whether or not I invest.

WYG_04

Basically, I write up what the company does and why they’re different…

  • The terms of the deal…
  • Their competition…
  • Why this particular team does or doesn’t have the ability to make the company successful…
  • The key risks and potential roadblocks…
  • What has to go right for the company to return 10, 50, or 100 times my money…

This memo gives me a clear picture of why I’m investing or not.

And the more of these deals I do, the more valuable my old deal memos become.

It gives me a record to look back on.

If you pass on investing, and the company hits it big, you can look back and figure out why you missed the opportunity.

If you invest and the company gives you disappointing returns, you’ll be able to see where your thinking went wrong so you can avoid those mistakes in the future.

And if you decide to invest and a company makes you $1 million or more…

You’ll know what you saw so you can look for it again.

Writing deal memos is something I recommend everyone does with these venture opportunities.

MIKE WARD:

I absolutely agree.

And that’s why our team writes up our own deal memo for each of the opportunities we show our members.

Folks can use this as a template for writing their own.

Along with the pitch deck, the due diligence package and the deal memo, you’ll also get a terms sheet.

WYG_05

This is a very short document that lays out the exact terms of the deal.

It has the share price, the current valuation…

And it gives you a private contact information for the company who will provide you with all of the detailed information.

Once you read and understand the deal and decide it’s right for you, they will show you step by step how to move forward from there.

Now, if you’re in on any of these private deals, you’re going to want to keep up with all the developments.

WYG_06

So every month, our team sends out an investor update.

This covers all the important developments going on with all of the companies we’ve brought to our members.

We check in with their executive team.

We’ll cover any increases in the company valuation.

And we’ll discuss our thoughts on their exit potential.

Plus, every time there’s a major development, you’ll get a special email alert.

WYG_07

For example, when Emerald Health Pharmaceuticals releases the results of their Phase 1 trials… or when they begin a Phase 2 or 3 clinical trial… or when they get FDA approval for any of their drugs, you’ll be among the first to know.

MICHAEL ROBINSON:

There’s one more benefit to being a part of this venture that we need to talk about, Mike.

The Cannabis Venture Mastermind.

MIKE WARD:

That’s right, Michael.

When we bring you these opportunities, you may want to discuss them with other members.

It’s important to see how other folks are looking at them.

They may see a profit opportunity you didn’t know about.

Or they may have some industry knowledge you’re lacking.

That’s why we’ve set up the Cannabis Venture Mastermind. This online Mastermind lets you create your own forums with fellow members.

WYG_08

You can discuss all of the pitches…

What you like or don’t like about each of the startups…

And whether or not you’re investing in the companies…

MICHAEL ROBINSON:

Plus, being a part of this Mastermind has another advantage.

When you start becoming known as a successful startup investor, you’re going to find that other startups are going to want to seek you out.

So you can bring these deals to the Mastermind and share the opportunities with the other members.

That means, on top of the four to six deals our team presents every year, you could potentially get access to a dozen more.

That’s why it’s so important that you start writing the deal memos and really studying the due diligence packages we provide.

It’ll help set you up for success in all the other opportunities you come across.

MIKE WARD:

And this isn’t just your run of the mill research service where our readers are living in a virtual world… we’re going to be meeting up in the real world, too.

The National Institute for Cannabis Investors hosts one of the largest annual retreats in the industry.

This is where you’ll get to meet face to face with industry leaders and fellow members.

As a member of the Cannabis Venture Syndicate, we’ll pay for your ticket. And we’ll give you a complementary guest pass.

WYG_09

At this event, we’re going to host a private meeting just for the Masterminds.

We’ll be inviting CEOs and executives from close to a dozen cannabis companies.

  • Some with brand new startups that we really love...
  • Some from private companies run by our board members. Avtar and his CEO will be there...
  • And we’ll have CEOs of from companies that have already gone public.

You’ll get to see their presentations live and ask them questions.

And whether or not you invest, you’ll get to put them in your Rolodex.

You will want to keep in contact with these guys. Because even if you feel that they’re not a good investment for you at the moment, they may be in a few months or years. Now, this is a serious opportunity.

And we’re dedicating a lot of resources to a small group of members.

So the Cannabis Venture Syndicate is not cheap.

MICHAEL ROBINSON:

Mike, the cost here is actually a steal.

See, in a traditional syndicate, you’re going to get charged what’s called a “carry” every time you exit a position.

In most syndicates that rate is 20%.

So say you put $10,000 into a company, and in nine months or maybe a year, that investment is up 2,000%.

Congratulations! It’s worth $200,000!

But you haven’t made $200,000. Because you owe the leader of the syndicate 20%.

That’s a $40,000 fee you just had to pay.

Or even, imagine we get extraordinarily lucky. We hit one of those 10,000% winners. The company shoots up 100 times.

Your investment is up to $1 million.

If you’re in a regular syndicate, you’re fee for that is $200,000.

Now, that fee is obviously worth it.

You made $800,000.

But that's not how we operate the Cannabis Venture Syndicate.

We provide you with information on each company on a silver platter.

If you had chosen to invest, you'd keep the whole million.

MIKE WARD:

Which is why our normal annual price is only $6,950.

However, you're not going to pay anywhere near that today.

We have a special offer for our Premier Class that can put thousands of dollars back into your pocket immediately.

Now you can spend this money any way you want.

However, if you choose to invest that money in this first deal, it's more than enough to potentially make you a million dollars, based on the numbers we've looked at today.

Now, I’d like to invite you to become an inaugural member of the Cannabis Venture Syndicate.

As soon as you subscribe, you’ll be rushed a digital welcome kit.

This includes…

  • The Emerald Health Pharmaceuticals Pitch Deck and Investor Presentation.
  • Our Due Diligence Package covering everything you need to know about the company.
  • Our Deal Memo on this opportunity.
  • The Terms Sheet with all of the details you need to move forward with this opportunity.
  • And you’ll also receive our Private Investing Primer, revealing everything you need to know to help you become a successful private investor.

Beyond that…

You’ll receive up to five more opportunities to invest in private companies over the next year.

Some of these deals are brought to us by Michael and vetted by our team of experts here at the National Institute for Cannabis Investors. Others could be deals we’ve been presented on our own.

We’ll give you…

  • Monthly updates on all of the deals…
  • Instant updates by email – and, if you want, text message – whenever there’s a new development...
  • Access to the Cannabis Venture Mastermind, so you can start connecting with fellow members right away.

Plus, we’ll send you tickets to our annual retreat, where you’ll get to meet with a dozen new private companies ready to pitch you.

At this event we’ll have a private dinner. Steak, lobster, top-shelf drinks. It’s all on the house for Cannabis Venture Syndicate members.

WYG_ALL

However, you’ll have to act fast.

There’s very limited availability.

And when we reach our cap, that’s it.

We’re closing the doors, and it could be years before we can let new subscribers in.

MICHAEL ROBINSON:

That’s right, Mike.

And I believe this first opportunity with Emerald Health Pharmaceuticals is going to be life changing.

Especially for folks who have never invested in a private company before.

MIKE WARD:

Absolutely, Michael.

It could be the kind of rare and exceptional opportunity that turns $10,000 into over $200,000 with TGOD…

Bigger than the opportunity to make over $379,000 from Tilray…

And even bigger than the $3.2 million private investors could have made from Aurora.

C_40

It’s impossible to know, but the potential is amazing.

Once you start seeing the kind of returns that can be available to private investors, you’ll never be the same again.

Michael, I can't thank you enough for being here today.

Your insights have been invaluable. And I look forward to working with you on many more of these deals over the next year.

MICHAEL ROBINSON:

Mike, it's been an absolute pleasure.

MIKE WARD:

Folks…

Right here, right now, you have the chance to enter the arena of startup investing.

Now you can join the 0.1 percent of Americans who drive our economy forward –and stake your claim to the kind of money that lasts for generations.

All you have to do is click the button below and you’ll be taken to a brief form where you can secure one of the limited membership spots available today.

If you have any questions about the National Institute for Cannabis Investors and how it will work for you, I encourage you to contact our reliable customer service team at 866.298.7257 or 443.380.2078 (international) and mention Priority Code: WCVSV373.

For the National Institute for Cannabis Investors, I’m Mike Ward.